Letter to the Editor: How We Treat Metastatic Castration-Sensitive Prostate Cancer.
作者信息
Daungsupawong Hinpetch, Wiwanitkit Viroj
机构信息
Private Academic Consultant, Phonhong, Lao People's Democratic Republic.
Department of Research Analytics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai, India.
出版信息
Cancer Control. 2024 Jan-Dec;31:10732748241286664. doi: 10.1177/10732748241286664.
Abstract
摘要
相似文献
1
Letter to the Editor: How We Treat Metastatic Castration-Sensitive Prostate Cancer.致编辑的信：我们如何治疗转移性去势敏感性前列腺癌。
Cancer Control. 2024 Jan-Dec;31:10732748241286664. doi: 10.1177/10732748241286664.
2
Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever.多西他赛治疗转移性激素敏感型前列腺癌：急需降低中性粒细胞减少性发热风险。
Eur Urol. 2016 Nov;70(5):707-708. doi: 10.1016/j.eururo.2016.06.041. Epub 2016 Jul 12.
3
RE: Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.关于：骨改良剂在转移性去势敏感性前列腺癌中的真实世界应用。
J Natl Cancer Inst. 2022 Apr 11;114(4):635-636. doi: 10.1093/jnci/djab216.
4
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancer.对于转移性激素敏感性前列腺癌，应首先使用化疗而非雄激素受体靶向治疗。反对意见：新型口服药物为转移性激素敏感性前列腺癌的化疗提供了一种有吸引力的替代方案。
Curr Opin Urol. 2020 Jul;30(4):620-622. doi: 10.1097/MOU.0000000000000694.
5
Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions.转移性前列腺癌治疗的最新进展：优化现有疗法的应用，同时寻找新的干预措施。
Curr Opin Oncol. 2018 May;30(3):159-164. doi: 10.1097/CCO.0000000000000443.
6
Modern treatment of metastatic prostate cancer.转移性前列腺癌的现代治疗
Tidsskr Nor Laegeforen. 2017 Jun 6;137(11):803-805. doi: 10.4045/tidsskr.16.0265. eCollection 2017 Jun.
7
Androgen pathway resistance in prostate cancer and therapeutic implications.前列腺癌中的雄激素途径抗性及其治疗意义。
Expert Opin Pharmacother. 2015;16(10):1521-37. doi: 10.1517/14656566.2015.1055249. Epub 2015 Jun 12.
8
Interstitial Lung Disease Caused by Apalutamide for Metastatic Castration-Sensitive Prostate Cancer.阿帕鲁胺治疗转移性去势敏感性前列腺癌所致间质性肺疾病
Arch Bronconeumol. 2024 Aug;60(8):537-538. doi: 10.1016/j.arbres.2024.04.009. Epub 2024 Apr 25.
9
Upfront metastasis‑directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in response to Onal's letter to the editor.
Med Oncol. 2021 Sep 28;38(11):136. doi: 10.1007/s12032-021-01583-x.
10
Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.系统治疗对有内脏转移的前列腺癌患者的疗效：系统评价、荟萃分析和网络荟萃分析。
J Urol. 2023 Sep;210(3):416-429. doi: 10.1097/JU.0000000000003594. Epub 2023 Jun 20.
本文引用的文献
1
How We Treat Metastatic Castration-Sensitive Prostate Cancer.转移性去势敏感性前列腺癌的治疗方法。
Cancer Control. 2024 Jan-Dec;31:10732748241274190. doi: 10.1177/10732748241274190.
Zotero 插件